Harmony Biosciences Enters Definitive Agreement To Acquire Zynerba Pharmaceuticals For Total Potential Consideration Of Up To $200M In Cash
Portfolio Pulse from Benzinga Newsdesk
Harmony Biosciences (HRMY) has entered into a definitive agreement to acquire Zynerba Pharmaceuticals (ZYNE) for a total potential consideration of up to $200 million in cash. The purchase price is $1.1059 per share, or $60 million in aggregate, plus one non-tradeable contingent value right (CVR) per share, representing the right to receive potential additional payments of up to $140 million.
August 14, 2023 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences is acquiring Zynerba Pharmaceuticals, which could potentially expand its product portfolio and market reach.
The acquisition of Zynerba Pharmaceuticals by Harmony Biosciences could potentially expand Harmony's product portfolio and market reach, which could lead to increased revenues and profitability in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Zynerba Pharmaceuticals is being acquired by Harmony Biosciences for a total potential consideration of up to $200 million in cash.
The acquisition of Zynerba Pharmaceuticals by Harmony Biosciences could potentially provide a significant cash infusion for Zynerba, which could be used to fund future growth initiatives.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100